Inquiry Basket
Loading ......
Filter By Product Search for
REL
REL Full Name
v-rel avian reticuloendotheliosis viral oncogene homolog
REL Introduction
REL (v-rel avian reticuloendotheliosis viral oncogene homolog), commonly known as c-Rel, is a member of the NF-κB family of transcription factors and serves as a central regulator of immune activation, cell survival, proliferation, and inflammatory signaling. As a DNA-binding transcription factor, c-Rel controls the expression of genes involved in adaptive and innate immune responses, making it particularly important in lymphocyte development, antigen presentation, and cytokine production. Researchers and drug developers are increasingly interested in REL because dysregulated NF-κB signaling is a well-established driver of cancer, chronic inflammation, and immune dysfunction. Unlike some NF-κB family members that are broadly expressed, c-Rel exhibits more specialized functions within immune cell populations, providing an attractive opportunity for targeted therapeutic intervention while potentially minimizing systemic toxicity. Growing evidence suggests that REL functions not only as a downstream signaling mediator but also as a master transcriptional regulator that shapes disease-specific immune programs.
The biological significance of REL is especially evident in oncology, where c-Rel has emerged as a critical oncogenic factor in multiple hematological malignancies. Elevated REL expression, gene amplification, and constitutive nuclear localization have been observed in several B-cell cancers, particularly germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL). Functional studies demonstrate that sustained c-Rel activity promotes tumor cell survival, enhances resistance to apoptosis, and supports malignant proliferation through the transcriptional activation of pro-survival and cell-cycle regulatory genes. Beyond its direct tumor-intrinsic role, c-Rel also contributes to the immunosuppressive tumor microenvironment. Recent studies have identified c-Rel as an important regulator of myeloid-derived suppressor cells (MDSCs), which inhibit anti-tumor immune responses and facilitate cancer progression. Experimental silencing of REL reduces MDSC accumulation and suppresses tumor growth, highlighting c-Rel as a promising target for next-generation cancer immunotherapies, including RNA-based and nanoparticle-mediated therapeutic approaches.
In addition to cancer, REL has become increasingly recognized as a key mediator of chronic inflammatory and cardiovascular diseases. Elevated c-Rel activity has been linked to autoimmune disorders such as psoriasis, where it regulates dendritic cell activation and promotes Th17-driven inflammatory responses that contribute to disease progression. Deficiency or inhibition of c-Rel has been shown to reduce pathogenic immune polarization and attenuate inflammatory skin lesions, supporting its potential as a therapeutic target for immune-mediated disorders. Emerging cardiovascular research further reveals that endothelial c-Rel contributes to atherosclerosis by coordinating inflammatory signaling, oxidative stress responses, and vascular cell proliferation in regions exposed to disturbed blood flow. Genetic deletion of c-Rel in endothelial cells significantly reduces plaque formation in experimental models, suggesting a previously underappreciated role in vascular disease. Collectively, current evidence positions REL as a multifunctional disease-associated transcription factor at the intersection of immunity, inflammation, cancer biology, and cardiovascular pathology, making it an increasingly valuable target for precision medicine and translational drug discovery.
Alternate Names for REL
REL; v-rel avian reticuloendotheliosis viral oncogene homolog; C-Rel; proto-oncogene c-Rel; oncogene REL, avian reticuloendotheliosis;
Loading ......
